NOCTURIA MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025-2032)

Nocturia Market , By Drug Class (Antidiuretic Agents (e.g., vasopressin analogs such as desmopressin), Alpha-1 Adrenergic Antagonists (e.g., tamsulosin, alfuzosin, silodosin, terazosin), Anticholinergic Agents (e.g., oxybutynin, tolterodine, solifenacin, darifenacin, trospium), Beta-3 Adrenergic Agonists (e.g., mirabegron, vibegron), Loop Diuretic Timing Therapies (e.g., furosemide administered in late-afternoon dosing), and Combination Pharmacotherapies (e.g., mirabegron + solifenacin, alpha-blocker + anticholinergic)), By Route of Administration (Oral, Intranasal, Sublingual/orodispersible, and Parenteral and other systemic routes), By Dosage Form (Immediate-release tablets or capsules, Modified/extended-release oral formulations, Orodispersible tablets or film, Nasal sprays or drops, and Injectable formulations), By Mechanism of Action (Vasopressin Receptor Agonists, Smooth Muscle Relaxants, Muscarinic Receptor Blockers, Beta-3 Receptor Stimulants, Prostate-Targeted Relaxants, and Fluid-Regulation Modulators), By Prescription Type (Prescription-Only Medicines (Rx) and Over-the-Counter Options (OTC)), By Age Group (Adult and Geriatric), By Gender (Male and Female), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By End User (Hospitals, Specialty urology clinics, Long-term care and nursing facilities, and Home-care and self-administration settings), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East and Africa)

Published In: 11 Dec, 2025
Code: CMI9058
Pages: 151
Formats: Excel and PDF
Industry: Pharmaceutical
- Historical Range: 2020 - 2024
- Forecast Period: 2025 - 2032

The Global Nocturia Market is estimated to be valued at USD 4.41 Bn in 2025 and is expected to reach USD 7.61 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8.1% from 2025 to 2032. The global nocturia market represents a critical segment within the broader urological and sleep disorder therapeutics landscape, addressing a prevalent medical condition characterized by the need to wake up during the night to urinate. Nocturia affects millions of individuals worldwide, with prevalence rates increasing significantly with age, impacting both men and women across various demographic groups.

This condition not only disrupts sleep patterns but also substantially affects quality of life, leading to daytime fatigue, reduced productivity, and increased risk of falls among elderly populations. The market encompasses various treatment modalities including pharmacological interventions such as desmopressin, anticholinergics, and alpha-blockers, alongside non-pharmacological approaches including behavioral modifications and medical devices. Healthcare providers increasingly recognize nocturia as a distinct medical condition requiring targeted therapeutic intervention rather than merely a symptom of underlying disorders. The growing awareness among patients and healthcare professionals about available treatment options, coupled with an aging global population and rising prevalence of associated comorbidities such as diabetes, heart failure, and benign prostatic hyperplasia, continues to drive market expansion and innovation in therapeutic solutions.

Market Dynamics

The global nocturia market is primarily driven by several compelling factors that collectively contribute to robust market growth and expansion opportunities. The most significant driver is the rapidly aging global population, as nocturia prevalence increases substantially with age, affecting up to 80% of individuals over 65 years, creating an expanding patient base requiring therapeutic intervention. Rising awareness among healthcare providers and patients about nocturia as a treatable medical condition rather than an inevitable aspect of aging has led to increased diagnosis rates and treatment seeking behavior. Additionally, the growing prevalence of underlying conditions such as diabetes mellitus, cardiovascular diseases, and benign prostatic hyperplasia, which contribute to nocturia development, further expands the potential patient population.

However, the market faces notable restraints including limited awareness among patients leading to underdiagnosis and undertreatment, with many individuals accepting the condition as a normal part of aging without seeking medical intervention. Regulatory challenges for new drug approvals, particularly given the complex etiology of nocturia and the need for comprehensive safety profiles, can delay market entry of innovative treatments. High treatment costs and limited insurance coverage for certain therapeutic options may restrict patient access to optimal care. Despite these challenges, significant opportunities exist through technological advancement in diagnostic tools enabling better patient stratification and personalized treatment approaches. The development of novel therapeutic targets and combination therapies presents substantial growth potential, while expanding healthcare infrastructure in emerging markets offers new revenue streams for market participants seeking global expansion.

Key Features of the Study

This report provides in-depth analysis of the global nocturia market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global nocturia market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Ferring Pharmaceuticals, Astellas Pharma Inc., Pfizer Inc., AbbVie Inc., Merck & Co., Inc., Sanofi S.A., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Ltd., Avadel Pharmaceuticals plc, Sumitomo Pharma Co., Ltd., Urigen Pharmaceuticals Inc., Vantia Therapeutics Ltd., Viatris Inc., Allergan (an AbbVie company).
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global nocturia market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global nocturia market

Market Segmentation

Drug Class Insights (Revenue, USD Bn, 2020 - 2032)
- Antidiuretic Agents (e.g., vasopressin analogs such as desmopressin)
- Alpha-1 Adrenergic Antagonists (e.g., tamsulosin, alfuzosin, silodosin, terazosin)
- Anticholinergic Agents (e.g., oxybutynin, tolterodine, solifenacin, darifenacin, trospium)
- Beta-3 Adrenergic Agonists (e.g., mirabegron, vibegron)
- Loop Diuretic Timing Therapies (e.g., furosemide administered in late-afternoon dosing)
- Combination Pharmacotherapies (e.g., mirabegron + solifenacin, alpha-blocker + anticholinergic)
Route Of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Oral
- Intranasal
- Sublingual/orodispersible
- Parenteral and other systemic routes
Dosage Form Insights (Revenue, USD Bn, 2020 - 2032)
- Immediate-release tablets or capsules
- Modified/extended-release oral formulations
- Orodispersible tablets or film
- Nasal sprays or drops
- Injectable formulations
Mechanism Of Action Insights (Revenue, USD Bn, 2020 - 2032)
- Vasopressin Receptor Agonists
- Smooth Muscle Relaxants
- Muscarinic Receptor Blockers
- Beta-3 Receptor Stimulants
- Prostate-Targeted Relaxants
- Fluid-Regulation Modulators
Prescription Type Insights (Revenue, USD Bn, 2020 - 2032)
- Prescription-Only Medicines (Rx)
- Over-the-Counter Options (OTC)
Age Group Insights (Revenue, USD Bn, 2020 - 2032)
- Adult
- Geriatric
Gender Insights (Revenue, USD Bn, 2020 - 2032)
- Male
- Female
Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
End User Insights (Revenue, USD Bn, 2020 - 2032)
- Hospitals
- Specialty urology clinics
- Long-term care and nursing facilities
- Home-care and self-administration settings
Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
  - U.S.
  - Canada
- Latin America
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
- Europe
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
- Asia Pacific
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
- Middle East
  - GCC Countries
  - Israel
  - Rest of Middle East
- Africa
  - South Africa
  - North Africa
  - Central Africa
Key Players Insights
- Ferring Pharmaceuticals
- Astellas Pharma Inc.
- Pfizer Inc.
- AbbVie Inc.
- Merck & Co., Inc.
- Sanofi S.A.
- GlaxoSmithKline plc
- Teva Pharmaceutical Industries Ltd.
- Glenmark Pharmaceuticals Ltd.
- Avadel Pharmaceuticals plc
- Sumitomo Pharma Co., Ltd.
- Urigen Pharmaceuticals Inc.
- Vantia Therapeutics Ltd.
- Viatris Inc.
- Allergan (an AbbVie company)

Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
Market Purview
- Report Description
  - Market Definition and Scope
- Executive Summary
  - Global Nocturia Market, By Drug Class
  - Global Nocturia Market, By Route of Administration
  - Global Nocturia Market, By Dosage Form
  - Global Nocturia Market, By Mechanism of Action
  - Global Nocturia Market, By Prescription Type
  - Global Nocturia Market, By Age Group
  - Global Nocturia Market, By Gender
  - Global Nocturia Market, By Distribution Channel
  - Global Nocturia Market, By End User
  - Global Nocturia Market, By Region
Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER’s Analysis
- Merger and Acquisition Scenario
- Industry Trends
Global Nocturia Market, By Drug Class, 2020-2032, (USD Bn)
- Introduction
  - Market Share Analysis, 2025 and 2032 (%)
  - Y-o-Y Growth Analysis, 2021 - 2032
  - Segment Trends
- Antidiuretic Agents (e.g., vasopressin analogs such as desmopressin)
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Alpha-1 Adrenergic Antagonists (e.g., tamsulosin, alfuzosin, silodosin, terazosin)
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Anticholinergic Agents (e.g., oxybutynin, tolterodine, solifenacin, darifenacin, trospium)
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Beta-3 Adrenergic Agonists (e.g., mirabegron, vibegron)
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Loop Diuretic Timing Therapies (e.g., furosemide administered in late-afternoon dosing)
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Combination Pharmacotherapies (e.g., mirabegron + solifenacin, alpha-blocker + anticholinergic)
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Global Nocturia Market, By Route of Administration, 2020-2032, (USD Bn)
- Introduction
  - Market Share Analysis, 2025 and 2032 (%)
  - Y-o-Y Growth Analysis, 2021 - 2032
  - Segment Trends
- Oral
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Intranasal
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Sublingual/orodispersible
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Parenteral and other systemic routes
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Global Nocturia Market, By Dosage Form, 2020-2032, (USD Bn)
- Introduction
  - Market Share Analysis, 2025 and 2032 (%)
  - Y-o-Y Growth Analysis, 2021 - 2032
  - Segment Trends
- Immediate-release tablets or capsules
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Modified/extended-release oral formulations
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Orodispersible tablets or film
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Nasal sprays or drops
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Injectable formulations
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Global Nocturia Market, By Mechanism of Action, 2020-2032, (USD Bn)
- Introduction
  - Market Share Analysis, 2025 and 2032 (%)
  - Y-o-Y Growth Analysis, 2021 - 2032
  - Segment Trends
- Vasopressin Receptor Agonists
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Smooth Muscle Relaxants
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Muscarinic Receptor Blockers
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Beta-3 Receptor Stimulants
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Prostate-Targeted Relaxants
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Fluid-Regulation Modulators
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Global Nocturia Market, By Prescription Type, 2020-2032, (USD Bn)
- Introduction
  - Market Share Analysis, 2025 and 2032 (%)
  - Y-o-Y Growth Analysis, 2021 - 2032
  - Segment Trends
- Prescription-Only Medicines (Rx)
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Over-the-Counter Options (OTC)
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Global Nocturia Market, By Age Group, 2020-2032, (USD Bn)
- Introduction
  - Market Share Analysis, 2025 and 2032 (%)
  - Y-o-Y Growth Analysis, 2021 - 2032
  - Segment Trends
- Adult
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Geriatric
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Global Nocturia Market, By Gender, 2020-2032, (USD Bn)
- Introduction
  - Market Share Analysis, 2025 and 2032 (%)
  - Y-o-Y Growth Analysis, 2021 - 2032
  - Segment Trends
- Male
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Female
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Global Nocturia Market, By Distribution Channel, 2020-2032, (USD Bn)
- Introduction
  - Market Share Analysis, 2025 and 2032 (%)
  - Y-o-Y Growth Analysis, 2021 - 2032
  - Segment Trends
- Hospital Pharmacies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Global Nocturia Market, By End User, 2020-2032, (USD Bn)
- Introduction
  - Market Share Analysis, 2025 and 2032 (%)
  - Y-o-Y Growth Analysis, 2021 - 2032
  - Segment Trends
- Hospitals
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Specialty urology clinics
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Long-term care and nursing facilities
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Home-care and self-administration settings
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Global Nocturia Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
  - Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
  - Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
  - Regional Trends
- North America
  - Introduction
  - Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Mechanism of Action, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Prescription Type, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    - U.S.
    - Canada
- Latin America
  - Introduction
  - Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Mechanism of Action, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Prescription Type, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    - Brazil
    - Argentina
    - Mexico
    - Rest of Latin America
- Europe
  - Introduction
  - Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Mechanism of Action, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Prescription Type, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    - Germany
    - U.K.
    - Spain
    - France
    - Italy
    - Russia
    - Rest of Europe
- Asia Pacific
  - Introduction
  - Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Mechanism of Action, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Prescription Type, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    - China
    - India
    - Japan
    - Australia
    - South Korea
    - ASEAN
    - Rest of Asia Pacific
- Middle East
  - Introduction
  - Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Mechanism of Action, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Prescription Type, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    - GCC Countries
    - Israel
    - Rest of Middle East
- Africa
  - Introduction
  - Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Mechanism of Action, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Prescription Type, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
    - South Africa
    - North Africa
    - Central Africa
Competitive Landscape
- Ferring Pharmaceuticals
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Astellas Pharma Inc.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Pfizer Inc.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- AbbVie Inc.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Merck & Co., Inc.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Sanofi S.A.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- GlaxoSmithKline plc
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Teva Pharmaceutical Industries Ltd.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Glenmark Pharmaceuticals Ltd.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Avadel Pharmaceuticals plc
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Sumitomo Pharma Co., Ltd.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Urigen Pharmaceuticals Inc.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Vantia Therapeutics Ltd.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Viatris Inc.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Allergan (an AbbVie company)
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
References and Research Methodology
- References
- Research Methodology
- About us

*Browse 32 market data tables and 28 figures on 'Nocturia Market' - Global forecast to 2032

Limited Time Offer - Buy Now

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now